Academic medical centers in the US are voicing concern over reduced funding from the National Institutes of Health (NIH). While the issue is domestic, its effects may be global.
These institutions are key drivers of innovation far beyond the US, often laying the foundation for diagnostics, AI in healthcare, and advanced imaging breakthroughs. When public funding slows, private innovation can follow — across borders.
At Axcellant, we closely follow these developments, recognizing how early-stage research shapes the future of clinical advancements worldwide.
Explore how we support global innovation through smarter trial strategies.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant